Artivion’s AMDS PERSEVERE Trial: One-Year Clinical Outcomes in Complicated Acute Type I Aortic Dissections
At the 61st Annual Meeting of the Society of Thoracic Surgeons, held in Los Angeles, California, Artivion, Inc., a prominent cardiac and vascular surgery company, showcased the results of their AMDS PERSEVERE clinical trial. This trial focused on patients with acute Type I aortic dissections (ADTI) who underwent implantation of Artivion’s Aortic and Branch Endovascular Stent Graft System (AMDS).
Study Participants and Methods
The IDE cohort consisted of 93 study participants who underwent AMDS implantation. The primary endpoint was a composite of all-cause mortality, re-intervention, and stroke at one year following the procedure.
Clinical Outcomes at One Year
The presented data revealed that at one year following AMDS implantation, the all-cause mortality rate was 2.1%, with no reported strokes and a re-intervention rate of 3.2%. These results demonstrate a sustained benefit of AMDS in treating complicated acute Type I aortic dissections.
Impact on Individual Patients
For individuals diagnosed with acute Type I aortic dissections, these findings may offer hope for a successful treatment option. The low all-cause mortality rate, combined with the absence of strokes and only a small percentage requiring re-interventions, suggests that AMDS could significantly improve patient outcomes and reduce the risk of complications following the procedure.
Global Implications
The positive results from the AMDS PERSEVERE clinical trial may lead to a wider adoption of endovascular treatments for acute Type I aortic dissections. This could potentially reduce the number of open heart surgeries required, leading to shorter hospital stays, faster recovery times, and lower healthcare costs for patients. Furthermore, the benefits of AMDS could extend beyond the United States, as it is already CE-marked in Europe and approved in several other countries. The global impact of this technology could significantly improve patient care and outcomes in the field of cardiovascular surgery.
Conclusion
The AMDS PERSEVERE clinical trial, presented at the Society of Thoracic Surgeons meeting, showcased the sustained benefits of Artivion’s Aortic and Branch Endovascular Stent Graft System in treating complicated acute Type I aortic dissections. With impressive one-year clinical outcomes, including a low all-cause mortality rate, no reported strokes, and a minimal re-intervention rate, AMDS could offer a promising solution for patients diagnosed with this life-threatening condition. Furthermore, the potential global implications of this technology could lead to improved patient care, shorter hospital stays, and reduced healthcare costs.
- Artivion’s AMDS PERSEVERE clinical trial presented one-year outcomes for acute Type I aortic dissections
- Data revealed low all-cause mortality, no reported strokes, and minimal re-interventions
- AMDS could significantly improve patient outcomes and reduce complications
- Global implications include potential reduction in open heart surgeries and lower healthcare costs
